If you have been reading about mass spectrometry and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-09-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Dimethyl fumarate (DMF) is the methyl ester of fumaric acid. Dimethyl fumarate combined with three other fumaric acid esters (FAEs) is solely licensed in Germany as an oral therapy for psoriasis (brand name Fumaderm). Since 2013, it has been approved by the U.S. Food and Drug Administration (FDA) as a treatment option for adults with relapsing multiple sclerosis (brand name Tecfidera). In 2017, an oral formulation of dimethyl fumarate (brand name Skilarence) was approved for medical use in the European Union as a treatment for moderate-to-severe plaque psoriasis. Dimethyl fumarate is thought to have immunomodulatory properties without causing significant immunosuppression. Dimethyl fumarate has also been applied as a biocide in furniture or shoes to prevent growths of mold during storage or transport in humid climates. However, due to cases of allergic reactions after skin contact, dimethyl fumarate-containing consumer products are no longer authorised to be manufactured (since 1998) or imported (since 2009) in the European Union. Dimethyl fumarate is available as a generic medication.
It also came to be associated with Mexican cuisine, in large part due to national chain Chi-Chi's adopting a fried ice cream made with tortillas and cinnamon as its "signature dessert" when it opened in 1975. In Australia, fried ice cream is strongly associated with Asian cuisine and particularly Australian Chinese cuisine. It is frequently served with caramel sauce.
=== Early career === Early on as an independent investigator, Mrksich developed and executed the concept of dynamic substrates for cell culture. Here, self-assembled monolayers (SAMs) present cell adhesive ligands with perfect control over density and orientation against a non-adhesive, inert background, such as ethylene glycol. These monolayers can be further modified with electroactive groups that selectively release immobilized ligand when stimulated with an electric potential. Several strategies using this approach were studied in the context of cell signaling, migration, and co-culture. Subsequent cell-based work focused on developing methods to pattern cells on the aforementioned SAMs. The work has mostly utilized microcontact printing to confine adherent cells into defined positions, shapes, and sizes. Ultimately, his group's work has revealed examples of how cellular mechanics and cytoskeletal structure influence phenotype. A primary example of this involved investigating how cell shape exerts control over the differentiation of mesenchymal stem cells. Further work utilized these patterned monolayers to investigate the relationship between various cytoskeletal elements and to observe complex phenotypic differences in patient-derived neuroprogenitor cells. Recent work in the group investigating cell patterning has utilized photoactive adhesive peptides, allowing for local, spatiotemporal control of cell adhesion to study gap junction formation.
=== Emerging diseases === In most cases, microorganisms live in harmony with their hosts via mutual or commensal interactions. Diseases can emerge when existing parasites become pathogenic or when new pathogenic parasites enter a new host.
Gonnet, GH; Cohen, MA; Benner, SA (5 June 1992). "Exhaustive matching of the entire protein sequence database". Science. 256 (5062): 1443–5. doi:10.1126/science.1604319. PMID 1604319. – 1992 work presenting a PAM250 from a larger set of proteins than what Dayhoff had access to Jones, David T.; Taylor, William R.; Thornton, Janet M. (1992). "The rapid generation of mutation data matrices from protein sequences". Bioinformatics. 8 (3): 275–282. doi:10.1093/bioinformatics/8.3.275. – JTT model of 1992, with a clustering process to hopefully reduce the errors from a parismony assumption (i.e. assumption that each observed change happens directly, without intermediate changes; see discussion in doi:10.1093/oxfordjournals.molbev.a003851) Kosiol, Carolin; Goldman, Nick (February 2005). "Different Versions of the Dayhoff Rate Matrix". Molecular Biology and Evolution. 22 (2): 193–199. doi:10.1093/molbev/msi005. – analyses the extant variants of Dayhoff-PAM and proposes Direct Computation with Mutabilities (DCMut) variants of them.
Sources: en.wikipedia.org
Strategic Cyber Security, ISBN 978-9949-9040-7-5, 169 pages Halpern, Sue, "The Drums of Cyberwar" (review of Andy Greenberg, Sandworm: A New Era of Cyberwar and the Hunt for the Kremlin's Most Dangerous Hackers, Doubleday, 2019, 348 pp.), The New York Review of Books, vol. LXVI, no. 20 (19 December 2019), pp. 14, 16, 20. Harris, Shane (2014). @War: The Rise of the Military-Internet Complex. Eamon Dolan/Houghton Mifflin Harcourt. ISBN 978-0-544-25179-3. Hunt, Edward (2012). "US Government Computer Penetration Programs and the Implications for Cyberwar". IEEE Annals of the History of Computing. 34 (3): 4–21. Bibcode:2012IAHC...34c...4H. doi:10.1109/mahc.2011.82. S2CID 16367311. Kestner, Peter (2024). The Art of Cyber Warfare: Strategic and Tactical Approaches for Attack and Defense in the Digital Age (1st ed.). Wiesbaden: Springer. pp. XX, 292. doi:10.1007/978-3-658-43879-1. ISBN 978-3-658-43879-1. Janczewski, Lech; Colarik, Andrew M. (2007). Cyber Warfare and Cyber Terrorism. Idea Group Inc (IGI). ISBN 978-1-59140-992-2. Rid, Thomas (2012). "Cyber War Will Not Take Place". Journal of Strategic Studies. 35 (1): 5–32. doi:10.1080/01402390.2011.608939. S2CID 153828543. Springer, Paul J. (2025). Encyclopedia of Cyber Warfare (2nd ed.). New York: Bloomsbury Academic. p. 464. ISBN 9781440881619. Woltag, Johann-Christoph: 'Cyber Warfare' in Rüdiger Wolfrum (Ed.) Max Planck Encyclopedia of Public International Law (Oxford University Press 2012).
In veterinary practice, dogs are the species most commonly affected by hypothyroidism. The majority of cases occur as a result of primary hypothyroidism, of which two types are recognized: lymphocytic thyroiditis, which is probably immune-driven and leads to destruction and fibrosis of the thyroid gland, and idiopathic atrophy, which leads to the gradual replacement of the gland by fatty tissue. There is often lethargy, cold intolerance, exercise intolerance, and weight gain. Skin changes and fertility problems are seen in dogs with hypothyroidism, as well as many other symptoms. The signs of myxedema can be seen in dogs, with prominence of skin folds on the forehead, and cases of myxedema coma are encountered. The diagnosis can be confirmed by a blood test, as the clinical impression alone may lead to overdiagnosis. Lymphocytic thyroiditis is associated with detectable antibodies against thyroglobulin, although they typically become undetectable in advanced disease. Treatment is with thyroid hormone replacement. Other species that are less commonly affected include cats and horses, as well as other large domestic animals. In cats, hypothyroidism is usually the result of other medical treatments such as surgery or radiation. In young horses, congenital hypothyroidism has been reported predominantly in Western Canada and has been linked with the mother's diet.
=== Safety screening === DSC makes a reasonable initial safety screening tool. In this mode the sample will be housed in a non-reactive crucible (often gold or gold-plated steel), and which will be able to withstand pressure (typically up to 100 bar). The presence of an exothermic event can then be used to assess the stability of a substance to heat. However, due to a combination of relatively poor sensitivity, slower than normal scan rates (typically 2–3 °C/min, due to much heavier crucible) and unknown activation energy, it is necessary to deduct about 75–100 °C from the initial start of the observed exotherm to suggest a maximal temperature for the material. A much more accurate data set can be obtained from an adiabatic calorimeter, but such a test may take 2–3 days from ambient at a rate of a 3 °C increment per half-hour.
=== Ocular myxoma === Myxoma is a rare, benign stromal tumor of mesenchymal origin often confused with other conjunctival stromal tumors. Conjunctival myxomas are thought to originate in Tenon's capsule and can masquerade as conjunctival lymphoma, lymphangioma, ocular surface squamous neoplasia (OSSN), or amelanotic melanoma.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.